Dr. Jennifer Scalici,, MD
Claim this profileUSA Mitchell Cancer Institute
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
5 reported clinical trials
8 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
2Fallopian Tube Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Jennifer Scalici,, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
More about Jennifer Scalici,, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jennifer Scalici,, MD has experience with
- Bevacizumab
- Gemcitabine
- ZN-c3
- Mirvetuximab Soravtansine
- GEN-1
- ACR-368
Breakdown of trials Jennifer Scalici,, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasm
Serous Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer Scalici,, MD specialize in?
Jennifer Scalici,, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jennifer Scalici,, MD currently recruiting for clinical trials?
Yes, Jennifer Scalici,, MD is currently recruiting for 3 clinical trials in Mobile Alabama. If you're interested in participating, you should apply.
Are there any treatments that Jennifer Scalici,, MD has studied deeply?
Yes, Jennifer Scalici,, MD has studied treatments such as Bevacizumab, Gemcitabine, ZN-c3.
What is the best way to schedule an appointment with Jennifer Scalici,, MD?
Apply for one of the trials that Jennifer Scalici,, MD is conducting.
What is the office address of Jennifer Scalici,, MD?
The office of Jennifer Scalici,, MD is located at: USA Mitchell Cancer Institute, Mobile, Alabama 36604 United States. This is the address for their practice at the USA Mitchell Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.